In May 2025, the 19th International Conference on HIV Treatment, Pathogenesis, and Prevention Research (INTEREST 2025) was grandly held in Windhoek, the capital of Namibia. As a significant conference in the global HIV/AIDS prevention and treatment field, the INTEREST Conference focuses on AIDS challenges in Africa and low- to middle-income countries, building bridges for scientific breakthroughs and clinical practices.

At this conference, the first oral single-tablet fixed-dose combination anti-HIV new drug, Ainuomiti Tablets (ANV/3TC/TDF), independently developed by Chinese pharmaceutical company Jiangsu Aidea Pharmaceutical Co., Ltd. ("Aidea Pharma"), made its debut in Africa. With solid clinical data and breakthrough treatment concepts, it demonstrated the robust strength of China's pharmaceutical innovation to the world and injected new hope into the HIV/AIDS fight in Africa and even globally.

During the oral presentation session of the conference, Dr. Yü WANG from Aidea Pharma shared the 96-week data of the SPRINT study of Ainuomiti Tablets. This multi-center, randomized, double-blind, active-controlled Phase III clinical trial, led by Beijing Ditan Hospital affiliated with Capital Medical University, enrolled 762 virologically suppressed people living with HIV (PWH). The study's follow-up rate remained as high as 95%-99% throughout, providing a solid foundation for the reliability of the data.

The study results showed that whether participants continued treatment with Ainuomiti Tablets (NNRTI-based regimen) or switched from the imported drug EVG/Cobi/FTC/TAF (INSTI-based regimen) to Ainuomiti Tablets, the proportion of HIV RNA <50 copies/mL remained stable at 96.6% at 96 weeks, with a virological failure rate of only 2.1%. This fully confirms the excellent long-term viral suppression performance of this regimen. Meanwhile, the immune reconstitution capabilities of participants continued to strengthen, with CD4 cell counts significantly increasing from baseline at 96 weeks. Notably, the group switching from EVG/Cobi/FTC/TAF regimen to Ainuomiti Tablets saw an increase of 31.53 cells/μL, providing new clinical evidence for optimizing long-term immune function recovery in PWH.

Beyond its antiviral efficacy, Ainuomiti's breakthroughs in metabolic management are particularly striking. For a long time, weight gain and dyslipidemia have been common challenges for PWH receiving integrase inhibitor therapy. The SPRINT study showed that participants switching from EVG/Cobi/FTC/TAF regimen to Ainuomiti Tablets experienced an average weight loss of 0.66 kg at 96 weeks, with low-density lipoprotein cholesterol (LDL-C) levels decreasing by 0.30 mmol/L from baseline, while those continuing Ainuomiti Tablets treatment maintained stable weights. Additionally, the study confirmed the renal safety of Ainuomiti Tablets, with stable renal function indicators over 96 weeks, eliminating concerns about long-term medication use.

In addition to the oral presentation, Aidea Pharma also exhibited 6 subgroup research reports in the form of posters. These subgroup analyses deeply explored the performance of Ainuomiti Tablets in different dimensions, covering multiple aspects such as dyslipidemia related to blood lipid and atherosclerotic heart disease risk, changes in body weight, blood glucose and uric acid levels, the impact of concurrent cardiovascular diseases and related medications, general safety (including heart, liver, kidney, etc.), and applications in female subpopulations and groups with sexually transmitted diseases, comprehensively demonstrating the clinical value and application potential of Ainuomiti Tablets.

Africa bears approximately two-thirds of the global HIV population, and treatment accessibility and long-term health management have always been enormous challenges. For African regions with limited medical resources, the dual advantages of efficacy and metabolic protection demonstrated by China's innovative drug Ainuomiti Tablets undoubtedly provide a new option for optimizing treatment regimens. Ainuomiti's breakthrough concept of the "The Threefold Path to Health Treatment" (blood lipid management, weight management, and cardiovascular risk management) may advance the global HIV/AIDS treatment goal from "viral suppression" to "overall health improvement," particularly aligning with the urgent needs of African PWH to reduce complications and improve quality of life.

Aidea Pharma has always focused on the research and development of innovative chemical drugs, committed to meeting the urgent needs of AIDS treatment upgrades. As the only pharmaceutical enterprise from China and Asia to appear at the INTEREST 2025 Conference, Aidea Pharm has not only demonstrated its technological strength but also fulfilled its responsibility to safeguard global health. Today, Aidea Pharma is taking Africa as an important window to actively promote its independently developed high-quality anti-HIV drugs to international markets, especially in high-prevalence African regions.